Cargando…

Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway

BACKGROUND: Histone deacetylase (HDAC) inhibitors are emerging as a new class of anti-cancer drugs that promote cancer cell apoptosis, and include suberoylanilide hydroxamic acid (SAHA). The aim of this study was to investigate the mechanism of SAHA-induced apoptosis in human prostate cancer cell li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Xuan-Yan, Ding, Wei, Li, Tie-Qiu, Zhang, Yi-Xiong, Zhao, Shan-Chao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2017
Materias:	Molecular Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727751/ https://www.ncbi.nlm.nih.gov/pubmed/29211704 http://dx.doi.org/10.12659/MSM.904597

Ejemplares similares

In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC)
por: Tambunan, Usman SF, et al.
Publicado: (2011)

The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Restores Cardiomyocyte Contractility in a Rat Model of Early Diabetes
por: Bocchi, Leonardo, et al.
Publicado: (2019)

Molecular dynamics simulation of complex Histones Deacetylase (HDAC) Class II Homo Sapiens with suberoylanilide hydroxamic acid (SAHA) and its derivatives as inhibitors of cervical cancer
por: Tambunan, Usman Sumo Friend, et al.
Publicado: (2013)

The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Alleviates Salinity Stress in Cassava
por: Patanun, Onsaya, et al.
Publicado: (2017)

Effects of Treatment with Suppressive Combination Antiretroviral Drug Therapy and the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid; (SAHA) on SIV-Infected Chinese Rhesus Macaques
por: Ling, Binhua, et al.
Publicado: (2014)

Suberoylanilide Hydroxamic Acid (SAHA) Is a Driver Molecule of Neuroplasticity: Implication for Neurological Diseases
por: Verrillo, Lucia, et al.
Publicado: (2023)

Effects of Suberoylanilide Hydroxamic Acid (SAHA) on the Inflammatory Response in Lipopolysaccharide-Induced N9 Microglial Cells
por: Çelik, Zülfinaz Betül, et al.
Publicado: (2022)

Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma
por: O'Connor, O A
Publicado: (2006)

The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-γ
por: Klegeris, Andis, et al.
Publicado: (2012)

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, attenuates postoperative cognitive dysfunction in aging mice
por: Jia, Min, et al.
Publicado: (2015)

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
por: Min, Ahrum, et al.
Publicado: (2015)

The Anti-Tumor Effects and Molecular Mechanisms of Suberoylanilide Hydroxamic Acid (SAHA) on the Aggressive Phenotypes of Ovarian Carcinoma Cells
por: Chen, Shuo, et al.
Publicado: (2013)

Suberoylanilide Hydroxamic Acid (SAHA) Treatment Reveals Crosstalk Among Proteome, Phosphoproteome, and Acetylome in Nasopharyngeal Carcinoma Cells
por: Huang, Huichao, et al.
Publicado: (2022)

Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor
por: Richon, V M
Publicado: (2006)

Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Enhances Radiosensitivity and Suppresses Lung Metastasis in Breast Cancer In Vitro and In Vivo
por: Chiu, Hui-Wen, et al.
Publicado: (2013)

Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells
por: Zhou, Weiqiang, et al.
Publicado: (2016)

Effects of suberoylanilide hydroxamic acid (SAHA) combined with paclitaxel (PTX) on paclitaxel-resistant ovarian cancer cells and insights into the underlying mechanisms
por: Liu, Zhaohui, et al.
Publicado: (2014)

Transcriptional profiling of suberoylanilide hydroxamic acid (SAHA) regulated genes in mineralizing dental pulp cells at early and late time points
por: Duncan, Henry F., et al.
Publicado: (2015)

Suberoylanilide hydroxamic acid (SAHA) inhibits transforming growth factor-beta 2-induced increases in aqueous humor outflow resistance
por: Fujimoto, Tomokazu, et al.
Publicado: (2021)

In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model
por: Thiemann, Markus, et al.
Publicado: (2012)

Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells via the downregulation of nanog
por: Kumar, Bhavna, et al.
Publicado: (2015)

HDACi Valproic Acid (VPA) and Suberoylanilide Hydroxamic Acid (SAHA) Delay but Fail to Protect against Warm Hepatic Ischemia-Reperfusion Injury
por: Ruess, Dietrich A., et al.
Publicado: (2016)

The in vitro and vivo anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells
por: Lu, Hang, et al.
Publicado: (2016)

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells
por: Xu, Xing-dong, et al.
Publicado: (2014)

Autophagy-related genes are induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid via the activation of cathepsin B in human breast cancer cells
por: Han, Han, et al.
Publicado: (2017)

Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Improves Energetic Status and Cardiomyogenic Differentiation of Human Dilated Myocardium-Derived Primary Mesenchymal Cells
por: Miksiunas, Rokas, et al.
Publicado: (2020)

Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients
por: Sonnemann, Jürgen, et al.
Publicado: (2006)

Erratum to: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells
por: Xu, Xing-dong, et al.
Publicado: (2016)

Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth
por: Said, Thenaa K, et al.
Publicado: (2001)

Suberoylanilide hydroxamic acid represses glioma stem-like cells
por: Hsu, Che-Chia, et al.
Publicado: (2016)

ING5‐mediated antineuroblastoma effects of suberoylanilide hydroxamic acid
por: Wu, Ji‐cheng, et al.
Publicado: (2018)

Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities
por: Yang, Feifei, et al.
Publicado: (2019)

Hydroxamic Acid-Based Histone Deacetylase (HDAC) Inhibitors Bearing a Pyrazole Scaffold and a Cinnamoyl Linker
por: Zagni, Chiara, et al.
Publicado: (2019)

Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma
por: Yang, H, et al.
Publicado: (2015)

Suberoylanilide hydroxamic acid upregulates histone acetylation and activates endoplasmic reticulum stress to induce apoptosis in HepG2 liver cancer cells
por: Yu, Lei, et al.
Publicado: (2019)

A Novel Osteogenic Activity of Suberoylanilide Hydroxamic Acid is Synergized by BMP-2
por: Lee, Zang Hee, et al.
Publicado: (2015)

Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
por: Frühauf, Anton, et al.
Publicado: (2021)

Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells
por: Sun, Pei-Chang, et al.
Publicado: (2010)

Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma
por: Duvic, M, et al.
Publicado: (2006)

Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities
por: Zhao, Na, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kb9v99dl6245kc1lp4ok664aoc